科越医药

Kira Pharmaceuticals is a clinical-stage biotechnology company focused on developing next-generation complement-targeted therapies for patients with complement-mediated diseases. The company utilizes its proprietary LOGIC platform to discover and advance a pipeline of novel drugs that aim to provide superior efficacy and safety compared to existing treatments. Its lead candidate, KP104, is a first-in-class bifunctional biologic that simultaneously targets both the C5 and alternative complement pathways. Kira operates globally with offices in the United States and China, positioning itself to address significant unmet medical needs in immunology, hematology, and nephrology.